AUTHORS
Aliki Ntzifa, PhD, Eleni Theochari, MS2, Elina Lagopodi, MS3, Elena Themistokli, MS4, Ioannis Kostopoulos, PhD5, Ourania Tsitsilonis, MD,PhD6, Foteini Theodorakakou, MD7, Eirini Solia, MD8, Panagiotis Malandrakis, MD, MSc, PhD9, Nikolaos Kanellias, MD,PhD10, Evangelos Eleutherakis-Papaiakovou11, Ioannis Ntanasis-Stathopoulos, MD12, Evangelos Terpos, MD13, Maria Gavriatopoulou, MD14, Meletios-Athanasios (Thanos) C. Dimopoulos, MD15, Evi Lianidou, PhD16, Efstathios Kastritis, MD17
AFFILIATIONS
1 National and Kapodistrian University of Athens, Athens, Greece
2 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
3 National and Kapodistrian University of Athens, Athens, Greece
4 National and Kapodistrian University of Athens, Athens, Greece
5 National and Kapodistrian University of Athens, Athens, Greece
6 National and Kapodistrian University of Athens, Athens, Greece
7 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
8 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
9 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
10 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
11 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
12 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
13 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
14 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
15 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
16 National and Kapodistrian University of Athens, Athens, Greece
17 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
ABSTRACT
BACKGROUND: Invasive Bone Marrow (BM) assessments are currently the gold standard for diagnostic evaluation and clinical management of Multiple Myeloma (MM) and other monoclonal gammopathies, including early asymptomatic lesions. Minimal Residual Disease (MRD) detection has become an important endpoint for the evaluation of treatment efficacy and survival outcomes and is based in BM-based assessments. BM Next Generation Flow Cytometry (NGF) is a validated method for MRD assessment but is less sensitive for peripheral blood (PB)-based MRD evaluation. Conversely, circulating tumor cells (CTCs) have shown strong prognostic value in both symptomatic and asymptomatic myeloma and are gradually incorporated into routine risk stratification. Finally, molecular profiling of CTCs could enable patient genetic classification and longitudinal follow up of genetic alterations. The Circulating Multiple Myeloma Cell (CMMC) assay (Menarini Silicon Biosystems, Italy) has been developed for use in CellSearch® platform which is FDA-cleared for other types of cancer and offers a new tool for CMMC enumeration and downstream molecular characterization. The aim of this study was to compare the CMMC assay with the validated NGF method.
METHODS: Paired BM and PB samples were obtained from 391 consecutive patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) (total n=122), symptomatic MM at the time of diagnosis (n=77), during evaluation for MRD (n=166) and at MM relapse (n=26).The EuroFlow NGF protocol was used for BM evaluation, the detection of CTCs and their phenotypic characterization in BM and PB matched samples (sensitivity of 2x10-6). In parallel, PB samples collected in CellRescue tubes were analyzed with the CMMC assay for the enrichment (CD138+), detection and enumeration of CD38+/DAPI+/CD19-/CD45- circulating clonal plasma cells in PB using the CellSearch platform. PB was also collected from nine healthy donors (HDs), analyzed with the CMMC assay and used as control group. All analyses were performed independently and blindly. Comparisons were made between the two methods used for PB CTCs assessment with findings further evaluated in relation to corresponding bone marrow (BM) results only for the MRD group.
RESULTS: We initially assessed CMMs in the control group: the median number of CMMCs per 4mL of PB was 1 (range: 0-5); thus, all clinical samples with >5 CMMCs detected in CellSearch were defined as being positive. In the patients’ samples the median number of CMMCs per 4mL PB in CellSearch was 16 (range: 0-19,043) for those with MGUS/SMM, 2,247 (range: 0-46,642) for patients with NDMM, and 159 (range: 0-12,870) at MM relapses. For those evaluated at the time of MRD the median number of CMMCs was 1 (range: 0-60).Using an LOD of 0.0002% for NGF in PB samples, the overall concordance in PB between NGF and CMMC assay was 67.3% in MGUS/SMM, 92.3% in NDMM, and 95.8% at MM relapses. For the patients evaluated for MRD, the direct comparison between NGF-assessed BM samples with PB samples assessed with the CMMC assay revealed an overall agreement in 115/166 (69.3%) samples. In patients with BM-negative MRD (N=123/166, 74.1%), CMMC assay was positive in 19/123(15.4%) of cases (range 6-39 CMMCs) whereas 32/43 (74.4%) BM-positive MRD samples were negative by CMMC assay.
CONCLUSIONS: The CMMC assay is highly sensitive and can detect and enumerate CTCs in most patients with monoclonal gammopathies. Low CMMC counts require cautious interpretation in the context of other clinical data and should be confirmed by serial sampling. Given that the assay can also isolate CTCs, it provides further possibilities for their molecular characterization and could be a new tool for longitudinal non-invasive evaluations of the tumor load and dynamics. Our ongoing research will provide further data about the analytical performance of the CMMC assay, CTC molecular characterization and interchangeability with NGF.
DISCLOSURES
Efstathios Kastritis, MD: Genesis Pharma - Honoraria; GSK - Honoraria; Pfizer - Honoraria; Johnson and Johnson - Honoraria; Abbvie - Honoraria; Pfizer - Research Funding; Johnson and Johnson - Research Funding; GSK - Research Funding; Abbvie - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony)